Zirconium-89 belantamab

N/A

Report date: 2025/11/21 17:16:33

Base Information

Drug NameZirconium-89 belantamab
Drug Alias Name89Zr-GSK2857914
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyRadiation-emitting products > Radioactive diagnostic agentDiagnostic agent (In vivo) > Radionuclide Imaging agent +[6
Mechanisms of ActionPositron-emission tomography enhancersAnti-BCMA
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple MyelomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A